Abstract
The discovery of a neuroprotective treatment is a high priority for research in Parkinsons disease. Substantial progress has been made towards this goal in recent years, but at the present there is still no treatment which can be said to have proven neuroprotective effects. There is no single unifying model to account for the disease; indeed it seems likely that the etiology is a convergence of several causes. This multiplicity may prove helpful, because mitigation of only one or a few of the factors may produce clinically important benefit. This review emphasizes the strategies for discovery of new treatments. Current approaches to the development of neuroprotective treatments can be broadly characterized into three groups: 1) approaches based on the existing understanding of the mechanism of cell injury and death in PD; 2) approaches based on clues from the emerging knowledge of genetics of PD; and 3) approaches based on clues from the epidemiology and role of environmental factors in the etiology of PD. Some specific compounds and approaches are discussed to illustrate these strategies.
Keywords: Neuroprotective, Parkinson, genetics
Current Neuropharmacology
Title: Neuroprotective Strategies for Parkinsons Disease
Volume: 2 Issue: 3
Author(s): Ippolita Cantuti-Castelvetri and David G. Standaert
Affiliation:
Keywords: Neuroprotective, Parkinson, genetics
Abstract: The discovery of a neuroprotective treatment is a high priority for research in Parkinsons disease. Substantial progress has been made towards this goal in recent years, but at the present there is still no treatment which can be said to have proven neuroprotective effects. There is no single unifying model to account for the disease; indeed it seems likely that the etiology is a convergence of several causes. This multiplicity may prove helpful, because mitigation of only one or a few of the factors may produce clinically important benefit. This review emphasizes the strategies for discovery of new treatments. Current approaches to the development of neuroprotective treatments can be broadly characterized into three groups: 1) approaches based on the existing understanding of the mechanism of cell injury and death in PD; 2) approaches based on clues from the emerging knowledge of genetics of PD; and 3) approaches based on clues from the epidemiology and role of environmental factors in the etiology of PD. Some specific compounds and approaches are discussed to illustrate these strategies.
Export Options
About this article
Cite this article as:
Cantuti-Castelvetri Ippolita and Standaert G. David, Neuroprotective Strategies for Parkinsons Disease, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359585
DOI https://dx.doi.org/10.2174/1570159043359585 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
The Urokinase Receptor Interactome
Current Pharmaceutical Design Inhibition of Key Fungal (02) Protein(s) (Aspergillus fumigatus) In-Response to Treatment with Poly-Acid Ligand
Current Proteomics Review on the Protective Effects of PACAP in Models of Neurodegenerative Diseases In Vitro and In Vivo
Current Pharmaceutical Design Dynamic Medicinal Chemistry in the Elaboration of Morphine-6- Glucuronide Analogs
Current Topics in Medicinal Chemistry Perspectives of Protein Kinase C (PKC) Inhibitors as Anti-Cancer Agents
Mini-Reviews in Medicinal Chemistry The Targeted-liposome Delivery System of Antitumor Drugs
Current Drug Metabolism Biochemistry and Neurobiology of Prosaposin: A Potential Therapeutic Neuro-Effector
Central Nervous System Agents in Medicinal Chemistry Trafficking and Signaling of G Protein-Coupled Receptors in the Nervous System: Implications for Disease and Therapy
CNS & Neurological Disorders - Drug Targets Variability in the Effects of Nicotine on Different Regions of the Brain: Changes in the Concentration of Superoxide Dismutase Isoforms
Central Nervous System Agents in Medicinal Chemistry HLA-G Expression in Cancers: Potential Role in Diagnosis, Prognosis and Therapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Medicinal Value and Potential Therapeutic Mechanisms of Gynostemma pentaphyllum (Thunb.) Makino and Its Derivatives: An Overview
Current Topics in Medicinal Chemistry Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design GEFT, A Rho Family Guanine Nucleotide Exchange Factor, Regulates Lens Differentiation through a Rac1-Mediated Mechanism
Current Molecular Medicine <sup>11</sup>C-mHED for PET / CT: Principles of Synthesis, Methodology and First Clinical Applications
Current Radiopharmaceuticals Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Current Topics in Medicinal Chemistry Metformin: Repurposing Opportunities for Cognitive and Mood Dysfunction
CNS & Neurological Disorders - Drug Targets Potential Roles of HDAC Inhibitors in Mitigating Ischemia-induced Brain Damage and Facilitating Endogenous Regeneration and Recovery
Current Pharmaceutical Design Tumor Stroma Manipulation By MSC
Current Drug Targets Interleukin-15 in Gene Therapy of Cancer
Current Gene Therapy Metal Based Frameworks for Drug Delivery Systems
Current Topics in Medicinal Chemistry